Literature DB >> 24650642

Synthesis and structure-activity analysis of diphenylpyrazolodiazene inhibitors of the HIV-1 Nef virulence factor.

Prema C Iyer1, Jielu Zhao1, Lori A Emert-Sedlak2, Kerry K Moore3, Thomas E Smithgall4, Billy W Day5.   

Abstract

HIV-1 Nef is a critical AIDS progression factor yet underexplored target for antiretroviral drug discovery. A recent high-throughput screen for pharmacological inhibitors of Nef-dependent Src-family kinase activation identified a diphenylpyrazolodiazene hit compound with submicromolar potency in HIV-1 replication assays against a broad range of primary Nef variants. This compound, known as 'B9', binds directly to Nef and inhibits its dimerization in cells as a possible mechanism of action. Here were synthesized a diverse set of B9 analogs and identified structural features essential to antiretroviral activity. Chemical modifications to each of the three rings present in the parent compound were identified that did not compromise antiviral action. These analogs will guide the development of next-generation compounds with appropriate pharmacological profiles for assessment of antiretroviral activity in vivo.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiretroviral drug discovery; HIV Nef; HIV-1; Nef inhibitors

Mesh:

Substances:

Year:  2014        PMID: 24650642      PMCID: PMC3990189          DOI: 10.1016/j.bmcl.2014.02.045

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  18 in total

1.  Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions.

Authors:  L X Liu; N Heveker; O T Fackler; S Arold; S Le Gall; K Janvier; B M Peterlin; C Dumas; O Schwartz; S Benichou; R Benarous
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Importance of the nef gene for maintenance of high virus loads and for development of AIDS.

Authors:  H W Kestler; D J Ringler; K Mori; D L Panicali; P K Sehgal; M D Daniel; R C Desrosiers
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

Review 3.  HIV-1 accessory proteins--ensuring viral survival in a hostile environment.

Authors:  Michael H Malim; Michael Emerman
Journal:  Cell Host Microbe       Date:  2008-06-12       Impact factor: 21.023

Review 4.  Small molecule inhibitors of the HIV-1 virulence factor, Nef.

Authors:  Thomas E Smithgall; Gary Thomas
Journal:  Drug Discov Today Technol       Date:  2013-12

5.  High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection.

Authors:  R Mariani; F Kirchhoff; T C Greenough; J L Sullivan; R C Desrosiers; J Skowronski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.

Authors:  F Kirchhoff; T C Greenough; D B Brettler; J L Sullivan; R C Desrosiers
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

7.  A new reporter cell line to monitor HIV infection and drug susceptibility in vitro.

Authors:  A Gervaix; D West; L M Leoni; D D Richman; F Wong-Staal; J Corbeil
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

8.  New compounds: potential antidiabetics. IV. 1-(2,4-Dinitrophenyl)-3,5-diphenyl-4-arylazopyrazoles and 1-carbamoyl-3,5-diphenyl-4-arylazopyrazoles.

Authors:  H G Garg; P P Singh
Journal:  J Pharm Sci       Date:  1970-06       Impact factor: 3.534

9.  HIV-1 Nef dimerization is required for Nef-mediated receptor downregulation and viral replication.

Authors:  Jerrod A Poe; Thomas E Smithgall
Journal:  J Mol Biol       Date:  2009-09-23       Impact factor: 5.469

Review 10.  HIV-1 Nef: at the crossroads.

Authors:  John L Foster; J Victor Garcia
Journal:  Retrovirology       Date:  2008-09-22       Impact factor: 4.602

View more
  3 in total

1.  Dynamics of the Tec-family tyrosine kinase SH3 domains.

Authors:  Justin M Roberts; Sreya Tarafdar; Raji E Joseph; Amy H Andreotti; Thomas E Smithgall; John R Engen; Thomas E Wales
Journal:  Protein Sci       Date:  2016-03-18       Impact factor: 6.725

2.  Synthesis and evaluation of orally active small molecule HIV-1 Nef antagonists.

Authors:  Lori A Emert-Sedlak; H Marie Loughran; Haibin Shi; John L Kulp; Sherry T Shu; Jielu Zhao; Billy W Day; Jay E Wrobel; Allen B Reitz; Thomas E Smithgall
Journal:  Bioorg Med Chem Lett       Date:  2016-01-21       Impact factor: 2.823

3.  Engineering and Validation of a Vector for Concomitant Expression of Rare Transfer RNA (tRNA) and HIV-1 nef Genes in Escherichia coli.

Authors:  Siti Aisyah Mualif; Sin-Yeang Teow; Tasyriq Che Omar; Yik Wei Chew; Narazah Mohd Yusoff; Syed A Ali
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.